Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$3.8m

Galmed Pharmaceuticals Management

Management criteria checks 2/4

Galmed Pharmaceuticals' CEO is Allen Baharaff, appointed in Jan 2000, has a tenure of 26.5 years. total yearly compensation is $1.83M, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 1.57% of the company’s shares, worth $58.91K. The average tenure of the management team and the board of directors is 9.3 years and 10.6 years respectively.

Key information

Allen Baharaff

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage31.10%
CEO tenure26.5yrs
CEO ownership1.6%
Management average tenure9.3yrs
Board average tenure10.6yrs

Recent management updates

Recent updates

Analysis Article • May 16

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jan 06

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 04

Galmed GAAP EPS of -$0.15 beats by $0.09

Galmed press release (NASDAQ:GLMD): Q2 GAAP EPS of -$0.15 beats by $0.09. Cash and cash equivalents, restricted cash and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at December 31, 2021.
Analysis Article • May 03

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 15

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 02

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 20

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 04

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

The big shareholder groups in Galmed Pharmaceuticals Ltd. ( NASDAQ:GLMD ) have power over the company. Generally...
Analysis Article • Dec 06

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Allen Baharaff's remuneration changed compared to Galmed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$2mUS$570k

-US$10m

Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$9m

Mar 31 2025n/an/a

-US$7m

Dec 31 2024US$2mUS$553k

-US$8m

Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$551k

-US$7m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$605k

-US$18m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$632k

-US$32m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$503k

-US$29m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$1mUS$486k

-US$20m

Compensation vs Market: Allen's total compensation ($USD1.83M) is above average for companies of similar size in the US market ($USD659.91K).

Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.

CEO

Allen Baharaff (61 yo)

26.5yrs
Tenure
US$1,831,306
Compensation

Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...

Leadership Team

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founder26.5yrsUS$1.83m1.57%
$ 58.9k
Doron Cohen
Chief Financial Officer4.4yrsUS$362.53k0.34%
$ 12.6k
Guy Nehemya
COO & Data Protection Officer9.3yrsUS$402.84k0.34%
$ 12.6k
Yohai Stenzler
Chief Accounting Officer4.4yrsUS$410.36k0.34%
$ 12.6k
Liat Hayardeny
Chief Scientific Officer9.8yrsno data0%
$ 0
Tali Gorfine
Medical Consultant9.3yrsUS$382.51kno data
9.3yrs
Average Tenure
57.5yo
Average Age

Experienced Management: GLMD's management team is seasoned and experienced (9.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founderno dataUS$1.83m1.57%
$ 58.9k
David Sidransky
Lead Independent Director12.1yrsno data0.17%
$ 6.3k
Carol Brosgart
Independent Director9.1yrsno data0%
$ 0
José Mato de la Paz
Member of Scientific Advisory Boardno datano datano data
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Arun Sanyal
Member of Scientific Advisory Boardno datano datano data
Vlad Ratziu
Member of Scientific Advisory Boardno datano datano data
Shmuel Nir
Independent Director19.5yrsno data0.17%
$ 6.5k
Amir Poshinski
Independent Director6.1yrsno data0.17%
$ 6.3k
Shomron Ben-Horin
Member of Scientific Advisory Boardno datano datano data
10.6yrs
Average Tenure
65yo
Average Age

Experienced Board: GLMD's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 06:33
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galmed Pharmaceuticals Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Edward NashCanaccord Genuity
François BriseboisCraig-Hallum Capital Group LLC